Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06181656 · ClinicalTrials.gov registry record
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
A clinical trial of Esophageal Cancer and Pneumococcal Vaccine, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT06181656: Recruiting study of Esophageal Cancer and Pneumococcal Vaccine, sponsored by M.D. Anderson Cancer Center.
NCT06181656 is a study of Esophageal Cancer and Pneumococcal Vaccine that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06181656, a study of Esophageal Cancer and Pneumococcal Vaccine, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn how radiation treatment may affect your responses to vaccines against pneumonia.
Primary Outcome
Serologic responses will be calculated as the average fold change in antibody titer for each of 20 pneumococcal serotypes between baseline (time 0) and the first post-vaccination blood draw.
Conditions Studied
Interventions
- BIOLOGICAL Pneumonia vaccine
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2027-07-04 |
What NCT06181656 shows while recruiting
NCT06181656 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pneumonia vaccine is the first listed.
NCT06181656 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06181656 about?
NCT06181656 is a clinical study titled "Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation". To learn how radiation treatment may affect your responses to vaccines against pneumonia.
What is the current status of trial NCT06181656?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2024-02-05. Estimated completion is 2027-07-04.
What conditions does trial NCT06181656 study?
This clinical trial studies the following conditions: Esophageal Cancer, Pneumococcal Vaccine, Lymphopenia, Chemoradiation.
What interventions are being tested in trial NCT06181656?
The interventions under investigation include: Pneumonia vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06181656?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06181656 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06181656's enrollment target sits among peer trials
80 62nd of 123 higher than 61 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Registry for Esophageal and Gastroesophageal Junction Cancer
RECRUITING
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Retrospective Review of Esophageal Cancer at MSKCC
RECRUITING
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI